NCT05453396 2025-10-16
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
University of Washington
Phase 2 Recruiting
Clinical Trials
5 trialsNCT05672251 2025-10-06
Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
City of Hope Medical Center
Phase 2 Recruiting
NCT07197307 2025-09-29
CLEAR
Universität Münster
Phase 2 Not yet recruiting
NCT06918912 2025-04-09
LORELY
Istituto Clinico Humanitas
Phase 2 Recruiting
NCT05144009 2025-01-30
LOTIS-9
ADC Therapeutics S.A.
Phase 2 Terminated